Fortrea (FTRE) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
6 Aug, 2026Executive summary
Q3 2025 revenue reached $701.3 million, up 3.9% year-over-year, with adjusted EBITDA of $50.7 million and a backlog exceeding $7.6 billion; win rates and book-to-bill ratios hit multi-quarter highs.
Net loss for Q3 was $15.9 million, improved from $18.5 million in the prior year; year-to-date net loss was $953.7 million, driven by a $797.9 million goodwill impairment.
Operational excellence was highlighted by improved net promoter scores, faster site selection, and accelerated study recruitment.
CEO transition completed, with Anshul Thakral focusing on global engagement and operational excellence.
Continued focus on innovation, digital modernization, and AI-driven productivity gains.
Financial highlights
Adjusted EBITDA for Q3 was $50.7 million, down from $64.2 million year-over-year, with a margin of 7.2%; adjusted net income was $11.7 million, down from $20.7 million.
Operating loss for Q3 was $8.6 million, improved from $18.0 million in Q3 2024; year-to-date operating loss was $859.0 million, mainly due to goodwill impairment.
Free cash flow for Q3 was $79.5 million; year-to-date free cash flow was negative $33.3 million.
SG&A expenses fell 21.6% year-over-year, with $95 million in gross savings year-to-date.
Cash and cash equivalents at September 30, 2025, were $131.3 million; total debt was $1,124.2 million.
Outlook and guidance
2025 revenue guidance raised to $2.7–$2.75 billion; adjusted EBITDA guidance narrowed to $175–$195 million.
Management expects existing cash, cash flows, and credit facilities to be sufficient for at least the next 12 months.
SG&A optimization and cost reduction programs to continue into 2026, targeting further margin improvement.
Latest events from Fortrea
- Raised 2026 guidance after strong Q2 execution, improved profitability, and robust backlog.FTRE
Q2 2026 - Strong book-to-bill, commercial transformation, and debt reduction highlight strategic progress.FTRE
Jefferies 2024 Global Healthcare Conference - All director, auditor, and Say-on-Pay proposals were approved by requisite vote.FTRE
AGM 2026 - Demand, bookings, and technology integration are driving recovery and positioning for future growth.FTRE
Jefferies Global Healthcare Conference 2026 - Adjusted EBITDA rose to $47M as net loss narrowed and guidance was reaffirmed.FTRE
Q1 2026 - Annual meeting covers director elections, auditor ratification, and executive pay, with strong governance focus.FTRE
Proxy filing - Votes will be held on director elections, auditor ratification, and executive pay approval.FTRE
Proxy filing - 2025 results met guidance; 2026 targets margin growth and stability despite goodwill impairment.FTRE
Q4 2025 - Driving clinical trial modernization and margin expansion in a $40B global market.FTRE
44th Annual J.P. Morgan Healthcare Conference